Literature DB >> 12043842

Antiaggregating antibody raised against human PrP 106-126 recognizes pathological and normal isoforms of the whole prion protein.

E Hanan1, S A Priola, B Solomon.   

Abstract

Antibodies to the prion protein (PrP) have been critical to the neuropathological and biochemical characterization of PrP-related degenerative diseases in humans and animals. Although PrP is highly conserved evolutionarily, there is some sequence divergence among species; as a consequence, anti-PrP antibodies have a wide spectrum of reactivity when challenged with PrP from diverse species. We have produced an antibody [monoclonal antibody (mAb) 2-40] raised against a synthetic peptide corresponding to residues (106-126 of human PrP and have characterized it by epitope mapping, Western immunoblot analysis, and immunohistochemistry. The antibody recognizes not only human PrP isoforms but also pathological PrP from all species tested (i.e., sheep, hamsters, and mice). Together with the fact that it recognizes the whole PrP in both cellular and scrapie isoforms, mAb 2-40 may be helpful in studying conformational changes of the PrP, as well as establishing a possible connection between human and animal diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12043842     DOI: 10.1023/a:1015199904354

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   4.231


  21 in total

1.  Antibody binding defines a structure for an epitope that participates in the PrPC-->PrPSc conformational change.

Authors:  Z F Kanyo; K M Pan; R A Williamson; D R Burton; S B Prusiner; R J Fletterick; F E Cohen
Journal:  J Mol Biol       Date:  1999-11-05       Impact factor: 5.469

2.  PrP immunohistochemistry: different protocols, including a procedure for long formalin fixation, and a proposed schematic classification for deposits in sporadic Creutzfeldt-Jakob disease.

Authors:  N Privat; V Sazdovitch; D Seilhean; J L LaPlanche; J J Hauw
Journal:  Microsc Res Tech       Date:  2000-07-01       Impact factor: 2.769

3.  Immunomodulation of the human prion peptide 106-126 aggregation.

Authors:  E Hanan; O Goren; M Eshkenazy; B Solomon
Journal:  Biochem Biophys Res Commun       Date:  2001-01-12       Impact factor: 3.575

4.  Separation and properties of cellular and scrapie prion proteins.

Authors:  R K Meyer; M P McKinley; K A Bowman; M B Braunfeld; R A Barry; S B Prusiner
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

5.  The hydrophobic core sequence modulates the neurotoxic and secondary structure properties of the prion peptide 106-126.

Authors:  M F Jobling; L R Stewart; A R White; C McLean; A Friedhuber; F Maher; K Beyreuther; C L Masters; C J Barrow; S J Collins; R Cappai
Journal:  J Neurochem       Date:  1999-10       Impact factor: 5.372

6.  Synthetic peptides homologous to prion protein residues 106-147 form amyloid-like fibrils in vitro.

Authors:  F Tagliavini; F Prelli; L Verga; G Giaccone; R Sarma; P Gorevic; B Ghetti; F Passerini; E Ghibaudi; G Forloni
Journal:  Proc Natl Acad Sci U S A       Date:  1993-10-15       Impact factor: 11.205

7.  Neurotoxicity of a prion protein fragment.

Authors:  G Forloni; N Angeretti; R Chiesa; E Monzani; M Salmona; O Bugiani; F Tagliavini
Journal:  Nature       Date:  1993-04-08       Impact factor: 49.962

8.  Identification of prion amyloid filaments in scrapie-infected brain.

Authors:  S J DeArmond; M P McKinley; R A Barry; M B Braunfeld; J R McColloch; S B Prusiner
Journal:  Cell       Date:  1985-05       Impact factor: 41.582

9.  Biochemical differences among scrapie-associated fibrils support the biological diversity of scrapie agents.

Authors:  R J Kascsak; R Rubenstein; P A Merz; R I Carp; H M Wisniewski; H Diringer
Journal:  J Gen Virol       Date:  1985-08       Impact factor: 3.891

10.  Prion protein gene variation among primates.

Authors:  H M Schätzl; M Da Costa; L Taylor; F E Cohen; S B Prusiner
Journal:  J Mol Biol       Date:  1995-01-27       Impact factor: 5.469

View more
  5 in total

1.  In vitro neutralization of prions with PrP(Sc)-specific antibodies.

Authors:  Ryan Taschuk; Jacques Van der Merwe; Kristen Marciniuk; Andrew Potter; Neil Cashman; Philip Griebel; Scott Napper
Journal:  Prion       Date:  2015       Impact factor: 3.931

2.  Circumventing tolerance to the prion protein (PrP): vaccination with PrP-displaying retrovirus particles induces humoral immune responses against the native form of cellular PrP.

Authors:  Daphne Nikles; Patricia Bach; Klaus Boller; Christoph A Merten; Fabio Montrasio; Frank L Heppner; Adriano Aguzzi; Klaus Cichutek; Ulrich Kalinke; Christian J Buchholz
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

3.  Vitamin D 2 interacts with Human PrP(c) (90-231) and breaks PrP(c) oligomerization in vitro.

Authors:  Midori Suenaga; Yusuke Hiramoto; Yoichi Matsunaga
Journal:  Prion       Date:  2013-07-15       Impact factor: 3.931

4.  Detection and control of prion diseases in food animals.

Authors:  Peter Hedlin; Ryan Taschuk; Andrew Potter; Philip Griebel; Scott Napper
Journal:  ISRN Vet Sci       Date:  2012-02-29

5.  On the meaning of affinity limits in B-cell epitope prediction for antipeptide antibody-mediated immunity.

Authors:  Salvador Eugenio C Caoili
Journal:  Adv Bioinformatics       Date:  2012-11-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.